MELBOURNE, Australia, April 29, 2024 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated...
-- New $3.8 million DOD contract extension will fund non-clinical safety studies to support a three-month seasonal prophylaxis Phase 2b study in at-risk populations, comprising elderly individuals...
Ena Respiratory had to fillet the data to claim a win from its phase 2a flu prophylaxis trial, insisting its nasal spray could ultimately be effective against viruses like COVID-19 and the common cold.
Ena Respiratory has landed a spot on the Blue Knight program set up by Johnson & Johnson and the U.S. Biomedical Advanced Research and Development Authority, positioning it to benefit from mentorship as it seeks to hustle its infectious disease nasal spray to market.
SYDNEY, Australia, May 11, 2022 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for...
SYDNEY, Australia, Sept. 28, 2021 (GLOBE NEWSWIRE) -- ENA Respiratory, a biotechnology company developing a first-in-class nasal spray for the prevention of COVID-19 and other respiratory viral infections, announced today that it has engaged research partners PPD, Inc. and hVIVO, a division of Open Orphan, to conduct its Phase 2 studies. The self-administered nasal spray, INNA-051, is being developed to stimulate the innate immunity in the nose, where most respiratory viral infections begin. This announcement follows encouraging preliminary results from the ongoing Phase 1 study which supports decision to progress INNA-051 development to Phase 2 studies.
-- First-in-class, fast-acting nasal spray designed to boost innate immunity against respiratory viruses including SARS-CoV-2 and its variants, influenza and the common cold at the first entry portal for most infections
ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 mn Funding